Labcorp Holdings Inc. $LH Shares Sold by Wellington Management Group LLP

Key Points

• Wellington Management reduced its Labcorp stake by 10.8% in the second quarter, selling 103,543 shares and retaining 855,596 shares valued at approximately $239.6 million. Institutional investors collectively own 95.94% of Labcorp.
• Labcorp reported quarterly revenue of $3.73 billion and adjusted earnings of $4.99 per share, exceeding analyst expectations, while revenue increased 5.8% year over year. The company reaffirmed fiscal 2026 EPS guidance of $18.10–$18.55.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $330, while Labcorp declared a quarterly dividend of $0.72 per share, implying an annualized yield of about 0.9%.

Wellington Management Group LLP decreased its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 10.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 855,596 shares of the medical research company's stock after selling 103,543 shares during the quarter. Wellington Management Group LLP owned about 1.05% of Labcorp worth $239,567,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Victory Capital Management Inc. increased its stake in Labcorp by 103.1% in the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company's stock valued at $1,343,922,000 after purchasing an additional 2,719,475 shares during the period. Boston Partners acquired a new stake in shares of Labcorp during the fourth quarter worth about $480,271,000. Norges Bank acquired a new stake in shares of Labcorp during the fourth quarter worth about $248,006,000. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in shares of Labcorp during the second quarter worth about $168,222,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Labcorp during the second quarter worth about $142,125,000. Institutional investors and hedge funds own 95.94% of the company's stock.

Labcorp Stock Up 0.2%

LH opened at $335.90 on Monday. The firm has a 50 day moving average price of $300.21 and a 200 day moving average price of $278.96. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $341.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The company has a market cap of $27.24 billion, a PE ratio of 27.78, a price-to-earnings-growth ratio of 1.94 and a beta of 0.87.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping analysts' consensus estimates of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm had revenue of $3.73 billion during the quarter, compared to analysts' expectations of $3.71 billion. During the same period in the prior year, the company earned $4.35 EPS. The firm's revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts expect that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. Labcorp's dividend payout ratio (DPR) is currently 23.82%.

Insider Buying and Selling at Labcorp

In other news, CEO Adam H. Schechter sold 4,669 shares of Labcorp stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the sale, the chief executive officer directly owned 102,565 shares of the company's stock, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of Labcorp stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the sale, the executive vice president owned 6,956 shares in the company, valued at $2,133,683.44. This represents a 11.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 9,681 shares of company stock valued at $3,027,677. 0.84% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LH shares. Piper Sandler lifted their target price on Labcorp from $300.00 to $309.00 and gave the company a "neutral" rating in a research note on Tuesday, August 4th. Truist Financial lifted their price target on shares of Labcorp from $320.00 to $350.00 and gave the company a "buy" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on shares of Labcorp from $330.00 to $360.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Mizuho set a $355.00 target price on Labcorp in a report on Monday, August 10th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $306.00 price target on shares of Labcorp in a research note on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $330.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source